SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing intense volatility as investors weigh a major strategic partnership with NVIDIA against weaker-than-expected earnings results. The community is actively debating the stock's long-term potential as an AI infrastructure powerhouse versus the immediate risks of capital burn and share dilution.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending following a record Q1 earnings report that saw revenue climb significantly year-over-year while management raised its 2026 growth outlook. The community is actively debating a potential short squeeze, given the high short interest and the company's newfound scale through major Big Tech engagements and profitability.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is seeing intense volatility as investors weigh the potential for a massive AI-driven infrastructure supercycle against concerns that the stock's parabolic ascent is detached from its underlying financials. While bullish sentiment is fueled by robust demand for 800G and 1.6T transceivers and optimistic capacity expansion plans, the community remains deeply divided, with many actively debating whether this is a legitimate long-term re-rating or a speculative bubble prone to a sharp correction.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the top trending stock as investors anticipate its Q1 earnings, fueled by optimism over a record $2.2 billion backlog and significant defense contracts, including a new partnership with Anduril. The community is actively debating the stock's potential to reach triple digits, with bullish sentiment driven by the company's aggressive vertical integration strategy and its perceived position as the primary Western competitor to SpaceX.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors digest a positive earnings report that showcased robust revenue growth and margin expansion, while the company continues to position itself for a leadership role in the emerging sports prediction market sector. Community sentiment remains mixed, with active debates centered on whether prediction platforms represent a long-term growth catalyst or a cannibalizing force that threatens traditional sportsbook operations.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as it trades near multi-year lows, sparking intense community debate over potential catalysts like a leadership appointment, a strategic buyout, or an aggressive short squeeze. Traders are actively weighing the company's turnaround efforts, including international expansion plans and operational improvements, against concerns over high debt and recent same-store sales performance.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as shareholders react to a recent lawsuit filed against distribution partner Nippon Shinyaku, with the community interpreting the move as a strategic effort to regain full control of deramiocel ahead of an anticipated August FDA decision. While some investors express short-term concern over legal uncertainty, many are using the pullback as a buying opportunity, viewing the litigation as a necessary maneuver to improve commercial economics and clear the path for a potential acquisition or independent launch.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors focus on its strategic pivot from bitcoin mining toward high-performance computing data centers, with community excitement centering on upcoming capacity expansion and anticipated hyperscaler partnerships at its Kentucky site. Despite recent earnings reports reflecting expected transition-related costs and revenue shifts, the stock is seeing significant interest from retail traders betting on its long-term infrastructure play and potential for a short squeeze.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors rally behind its pivot to a "Physical AI" and robotics infrastructure play, fueled by strong institutional interest and anticipation of its critical role in autonomous systems. Community members are actively highlighting the company's deep automotive backlog and cybersecurity credentials, with many expressing long-term optimism regarding a potential breakout driven by these strategic shifts.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility following its latest earnings report, where a revenue beat and strong organic growth were offset by an earnings-per-share miss and acquisition-related costs. The community is actively debating the stock's future, with many retail investors focusing on long-term growth potential and high short interest as catalysts for a possible squeeze, while skeptics emphasize concerns over profitability and acquisition strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bio-Rad to Participate in Upcoming Investor Conferences

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following...

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Here's Why...

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down   - Should You Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendat...

Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects

Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price

Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday...

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...

Bio-Rad Laboratories Q1 Earnings Call Highlights

Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continued weakness in academic research demand are weighing on growth and profitability expectations for th...

Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) announced its quarterly earnings data on Thursday. The medical research company reported $1.89 earnings per share for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million during the...

Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of -31.77% and +1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.84	--	--	N/A
Q1 '26	$1.97	$1.89	-4.21%	MISSED
Q4 '25	$2.71	$2.51	-7.31%	MISSED
Q3 '25	$1.95	$2.26	15.66%	BEAT
Q2 '25	$1.73	$2.61	50.52%	BEAT

BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest BIO News

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A